Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types

Prashant D. Tailor, Sai Karthik Kodeboyina, Shan Bai, Shruti Sharma, Akshay Ratnani, John A. Copland, Jin-Xiong She, Ashok Kumar Sharma, Nikhil Patel

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: The aim of this study was to compare and contrast the expression of all members of the Kallikrein (KLK) family of genes across 15 cancer types and to evaluate their utility as diagnostic and prognostic biomarkers. Results: Severe alterations were found in the expression of different Kallikrein genes across various cancers. Interestingly, renal clear cell and papillary carcinomas have similar kallikrein expression profiles, whereas, chromophobe renal cell carcinoma has a unique expression profile. Several KLK genes have excellent biomarker potential (AUC > 0.90) for chromophobe renal cell carcinoma (KLK2, KLK3, KLK4, KLK7, KLK15), renal papillary carcinoma (KLK1, KLK6, KLK7), clear cell renal cell carcinoma (KLK1, KLK6), thyroid carcinoma (KLK2, KLK4, KLK13, KLK15) and colon adenocarcinoma (KLK6, KLK7, KLK8, KLK10). Several KLK genes were significantly associated with mortality in clear cell renal cell carcinoma (KLK2: HR = 1.69; KLK4: HR = 1.63; KLK8: HR = 1.71; KLK10: HR = 2.12; KLK11: HR = 1.76; KLK14: HR = 1.86), papillary renal cell carcinoma (KLK6: HR = 3.38, KLK7: HR = 2.50), urothelial bladder carcinoma (KLK5: HR = 1.89, KLK6: HR = 1.71, KLK8: HR = 1.60), and hepatocellular carcinoma (KLK13: HR = 1.75). Methods: The RNA-seq gene expression data were downloaded from The Cancer Genome Atlas (TCGA). Statistical analyses, including differential expression analysis, receiver operating characteristic curves and survival analysis (Cox proportionalhazards regression models) were performed. Conclusions: A comprehensive analysis revealed the changes in the expression of different KLK genes associated with specific cancers and highlighted their potential as a diagnostic and prognostic tool.

Original languageEnglish (US)
Pages (from-to)17876-17888
Number of pages13
JournalOncotarget
Volume9
Issue number25
DOIs
StatePublished - Apr 1 2018

Fingerprint

Kallikreins
Renal Cell Carcinoma
Biomarkers
Genes
Neoplasms
Atlases
Papillary Carcinoma
Survival Analysis
Thyroid Neoplasms
ROC Curve
Area Under Curve
Hepatocellular Carcinoma
Colon
Urinary Bladder
Adenocarcinoma
Genome
RNA
Carcinoma
Kidney
Gene Expression

Keywords

  • Cancer
  • Gene expression
  • Kallikreins
  • Prognosis
  • TCGA

ASJC Scopus subject areas

  • Oncology

Cite this

Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types. / Tailor, Prashant D.; Kodeboyina, Sai Karthik; Bai, Shan; Sharma, Shruti; Ratnani, Akshay; Copland, John A.; She, Jin-Xiong; Sharma, Ashok Kumar; Patel, Nikhil.

In: Oncotarget, Vol. 9, No. 25, 01.04.2018, p. 17876-17888.

Research output: Contribution to journalArticle

Tailor, Prashant D. ; Kodeboyina, Sai Karthik ; Bai, Shan ; Sharma, Shruti ; Ratnani, Akshay ; Copland, John A. ; She, Jin-Xiong ; Sharma, Ashok Kumar ; Patel, Nikhil. / Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types. In: Oncotarget. 2018 ; Vol. 9, No. 25. pp. 17876-17888.
@article{89b634e333ac4ad1b69cd00f23426068,
title = "Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types",
abstract = "Purpose: The aim of this study was to compare and contrast the expression of all members of the Kallikrein (KLK) family of genes across 15 cancer types and to evaluate their utility as diagnostic and prognostic biomarkers. Results: Severe alterations were found in the expression of different Kallikrein genes across various cancers. Interestingly, renal clear cell and papillary carcinomas have similar kallikrein expression profiles, whereas, chromophobe renal cell carcinoma has a unique expression profile. Several KLK genes have excellent biomarker potential (AUC > 0.90) for chromophobe renal cell carcinoma (KLK2, KLK3, KLK4, KLK7, KLK15), renal papillary carcinoma (KLK1, KLK6, KLK7), clear cell renal cell carcinoma (KLK1, KLK6), thyroid carcinoma (KLK2, KLK4, KLK13, KLK15) and colon adenocarcinoma (KLK6, KLK7, KLK8, KLK10). Several KLK genes were significantly associated with mortality in clear cell renal cell carcinoma (KLK2: HR = 1.69; KLK4: HR = 1.63; KLK8: HR = 1.71; KLK10: HR = 2.12; KLK11: HR = 1.76; KLK14: HR = 1.86), papillary renal cell carcinoma (KLK6: HR = 3.38, KLK7: HR = 2.50), urothelial bladder carcinoma (KLK5: HR = 1.89, KLK6: HR = 1.71, KLK8: HR = 1.60), and hepatocellular carcinoma (KLK13: HR = 1.75). Methods: The RNA-seq gene expression data were downloaded from The Cancer Genome Atlas (TCGA). Statistical analyses, including differential expression analysis, receiver operating characteristic curves and survival analysis (Cox proportionalhazards regression models) were performed. Conclusions: A comprehensive analysis revealed the changes in the expression of different KLK genes associated with specific cancers and highlighted their potential as a diagnostic and prognostic tool.",
keywords = "Cancer, Gene expression, Kallikreins, Prognosis, TCGA",
author = "Tailor, {Prashant D.} and Kodeboyina, {Sai Karthik} and Shan Bai and Shruti Sharma and Akshay Ratnani and Copland, {John A.} and Jin-Xiong She and Sharma, {Ashok Kumar} and Nikhil Patel",
year = "2018",
month = "4",
day = "1",
doi = "10.18632/oncotarget.24947",
language = "English (US)",
volume = "9",
pages = "17876--17888",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "25",

}

TY - JOUR

T1 - Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types

AU - Tailor, Prashant D.

AU - Kodeboyina, Sai Karthik

AU - Bai, Shan

AU - Sharma, Shruti

AU - Ratnani, Akshay

AU - Copland, John A.

AU - She, Jin-Xiong

AU - Sharma, Ashok Kumar

AU - Patel, Nikhil

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Purpose: The aim of this study was to compare and contrast the expression of all members of the Kallikrein (KLK) family of genes across 15 cancer types and to evaluate their utility as diagnostic and prognostic biomarkers. Results: Severe alterations were found in the expression of different Kallikrein genes across various cancers. Interestingly, renal clear cell and papillary carcinomas have similar kallikrein expression profiles, whereas, chromophobe renal cell carcinoma has a unique expression profile. Several KLK genes have excellent biomarker potential (AUC > 0.90) for chromophobe renal cell carcinoma (KLK2, KLK3, KLK4, KLK7, KLK15), renal papillary carcinoma (KLK1, KLK6, KLK7), clear cell renal cell carcinoma (KLK1, KLK6), thyroid carcinoma (KLK2, KLK4, KLK13, KLK15) and colon adenocarcinoma (KLK6, KLK7, KLK8, KLK10). Several KLK genes were significantly associated with mortality in clear cell renal cell carcinoma (KLK2: HR = 1.69; KLK4: HR = 1.63; KLK8: HR = 1.71; KLK10: HR = 2.12; KLK11: HR = 1.76; KLK14: HR = 1.86), papillary renal cell carcinoma (KLK6: HR = 3.38, KLK7: HR = 2.50), urothelial bladder carcinoma (KLK5: HR = 1.89, KLK6: HR = 1.71, KLK8: HR = 1.60), and hepatocellular carcinoma (KLK13: HR = 1.75). Methods: The RNA-seq gene expression data were downloaded from The Cancer Genome Atlas (TCGA). Statistical analyses, including differential expression analysis, receiver operating characteristic curves and survival analysis (Cox proportionalhazards regression models) were performed. Conclusions: A comprehensive analysis revealed the changes in the expression of different KLK genes associated with specific cancers and highlighted their potential as a diagnostic and prognostic tool.

AB - Purpose: The aim of this study was to compare and contrast the expression of all members of the Kallikrein (KLK) family of genes across 15 cancer types and to evaluate their utility as diagnostic and prognostic biomarkers. Results: Severe alterations were found in the expression of different Kallikrein genes across various cancers. Interestingly, renal clear cell and papillary carcinomas have similar kallikrein expression profiles, whereas, chromophobe renal cell carcinoma has a unique expression profile. Several KLK genes have excellent biomarker potential (AUC > 0.90) for chromophobe renal cell carcinoma (KLK2, KLK3, KLK4, KLK7, KLK15), renal papillary carcinoma (KLK1, KLK6, KLK7), clear cell renal cell carcinoma (KLK1, KLK6), thyroid carcinoma (KLK2, KLK4, KLK13, KLK15) and colon adenocarcinoma (KLK6, KLK7, KLK8, KLK10). Several KLK genes were significantly associated with mortality in clear cell renal cell carcinoma (KLK2: HR = 1.69; KLK4: HR = 1.63; KLK8: HR = 1.71; KLK10: HR = 2.12; KLK11: HR = 1.76; KLK14: HR = 1.86), papillary renal cell carcinoma (KLK6: HR = 3.38, KLK7: HR = 2.50), urothelial bladder carcinoma (KLK5: HR = 1.89, KLK6: HR = 1.71, KLK8: HR = 1.60), and hepatocellular carcinoma (KLK13: HR = 1.75). Methods: The RNA-seq gene expression data were downloaded from The Cancer Genome Atlas (TCGA). Statistical analyses, including differential expression analysis, receiver operating characteristic curves and survival analysis (Cox proportionalhazards regression models) were performed. Conclusions: A comprehensive analysis revealed the changes in the expression of different KLK genes associated with specific cancers and highlighted their potential as a diagnostic and prognostic tool.

KW - Cancer

KW - Gene expression

KW - Kallikreins

KW - Prognosis

KW - TCGA

UR - http://www.scopus.com/inward/record.url?scp=85044828843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044828843&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24947

DO - 10.18632/oncotarget.24947

M3 - Article

AN - SCOPUS:85044828843

VL - 9

SP - 17876

EP - 17888

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 25

ER -